정효암 (University of California, Los Angeles (현 Kompass Diagnostics Inc.))

한빛사논문

조회210

University of California, Los Angeles (현 Kompass Diagnostics Inc.)

CV File 288 kb

Nat. Commun., 20 August 2024 | https://doi.org/10.1038/s41467-024-51067-5 Rapid single-tier serodiagnosis of Lyme disease

Rajesh Ghosh ^1,10, Hyou-Arm Joung ^2,3,10, Artem Goncharov ^2,3, Barath Palanisamy ¹, Kevin Ngo ¹, Katarina Pejcinovic ¹, Nicole Krockenberger ¹, Elizabeth J. Horn ⁴, Omai B. Garner ⁵, Ezdehar Ghazal ⁶, Andrew O’Kula ⁶, Paul M. Arnaboldi ^6,7, Raymond J. Dattwyler ^6,7, Aydogan Ozcan ^1,2,3,8,* & Dino Di Carlo ^1,3,9,*

¹Bioengineering Department, University of California, Los Angeles, CA 90095, USA.
²Electrical & Computer Engineering Department, University of California, Los Angeles, CA 90095, USA.
³California NanoSystems Institute (CNSI), University of California, Los Angeles, CA 90095, USA.
⁴Lyme Disease Biobank, Portland, Oregon, OR 97221, USA.
⁵Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA.
⁶Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY 10595, USA.
⁷Biopeptides, Corp, Ridgefield, CT 06877, USA.
⁸Department of Surgery, University of California, Los Angeles, CA 90095, USA.
⁹Department of Mechanical Engineering, University of California, Los Angeles, CA 90095, USA.
¹⁰These authors contributed equally: Rajesh Ghosh, Hyou-Arm Joung.

^*Corresponding authors: correspondence to Aydogan Ozcan or Dino Di Carlo

Abstract

Point-of-care serological and direct antigen testing offers actionable insights for diagnosing challenging illnesses, empowering distributed health systems. Here, we report a POC-compatible serologic test for Lyme disease (LD), leveraging synthetic peptides specific to LD antibodies and a paper-based platform for rapid, and cost-effective diagnosis. Antigenic epitopes conserved across Borrelia burgdorferi genospecies, targeted by IgG and IgM antibodies, are selected to develop a multiplexed panel for detection of LD antibodies from patient sera. Multiple peptide epitopes, when combined synergistically with a machine learning-based diagnostic model achieve high sensitivity without sacrificing specificity. Blinded validation with 15 LD-positive and 15 negative samples shows 95.5% sensitivity and 100% specificity. Blind testing with the CDC’s LD repository samples confirms the test accuracy, matching lab-based two-tier results, correctly differentiating between LD and look-alike diseases. This LD diagnostic test could potentially replace the cumbersome two-tier testing, improving diagnosis and enabling earlier treatment while facilitating immune monitoring and surveillance.

논문정보

형식Research article
게재일2024년 08월 (BRIC 등록일 2024-08-22)
연구진국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기